The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
Jim Murphy is Greenphire's CEO and leads the company's strategy and he says he is committed to fostering a culture of growth, innovation, excellence and employee satisfaction. Under his leadership, the company has expanded exponentially - in...
There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.
Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
A London-based start-up that says clinical trials are ‘the biggest bottleneck to improving human health’ is launching a number of ‘breakthrough’ treatments for conditions including tinnitus, insomnia and progressive childhood short-sightedness.
The US Food and Drug Administration will soon require researchers and companies seeking approval for late-stage clinical trials to submit a diversity plan for trial participants. Scott Gray, CEO of Clincierge, discusses how trial sponsors and CROs can...
A small molecule drug candidate from Algiax Pharmaceuticals can reduce excitability of neurons in relation to chronic pain, dampening signal and reducing pain, a study shows.
Studies show a wearable monitor, described as a ‘game changer’ in the fight against Parkinson’s Disease (PD) has proven it is more than 95% accurate, PD Neurotechnology says.
A drug that has the ability to ‘transform the landscape’ for people living with metastatic colorectal cancer (CRC) has been granted priority review by the US Food and Drug Administration (FDA).
A partnership has been formed between Allucent, a biopharma services provider, has partnered with Thread, a decentralized clinical trial (DCT) and eCOA technology provider to launch Allucent Patient Direct Trials, a DCT focusing on small and mid-sized...
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
With an increase in clinical studies demanding an increase in CRAs, we spoke to Sara Brannon, director of quality and training development, at ICON, to find out their approach to recruiting and how the industry is suffering due to a global shortage because...
A small molecule drug has been recommended by England’s National Institute for Health Care and Excellence (NICE) for the treatment of adults with moderate to severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation – or V3+ Framework.
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.
Cumulus Neuroscience has been given the clearance by the US Food and Drug Administration (FDA) and the company says this will accelerate treatments for neuropsychiatric and neurodegenerative disorders.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
A single-agent treatment for patients with relapsed or refractory myelodysplastic neoplasms has shown promising results, including overall survival, in a study.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
Symptom improvements have been hailed as ‘very compelling’ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
Only a few months after being bought out, the CDMO invests in its capabilities with a facility to support drug-device products and sterile fill-finish.
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
